DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here

    Atopic Dermatitis, Access and Reimbursement, EU5

    Publish Date: June 6, 2017

    Atopic Dermatitis Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so drug manufacturers can build their market access strategy and optimize brand positioning.

    • What are current prescribing practices for atopic dermatitis in the EU5, and how, if at all, are these impacted by payer policy?
    • To what extent are off-label conventional systemics such as methotrexate and off-label biologics like Novartis’ Xolair (omalizumab) used for moderate to severe atopic dermatitis? How do payers cover any such off-label prescribing?
    • What are payer and physician perspectives on promising but costly emerging agents such as Sanofi/Regeneron’s dupilumab?
    • What key market access challenges will manufacturers of novel atopic dermatitis therapies face? What can they do to encourage optimal pricing and reimbursement terms and to drive uptake?